Final results for gemcitabine with nab-paclitaxel in neoadjuvant treatment of resectable pancreatic adenocarcinoma: GAIN-1 study.

• DOI: 10.1200/jco.2014.32.15_suppl.e15201
• Publication Date: 2019-01-03T17:31:54Z
• Authors: Sarunas Sliesoraitis; Neelam Vijay Desai; Jose Gilberto Tre...; Steven J. Hughes; Robert Zlotecki; Judith L. Lightsey; Alison Marguerite...; Carmen Joseph All...; Long H. Dang; Karen Colleen Daily; Kevin Behrns; Chen Liu; Shailendra Chauhan; Amy L. Collinsworth; Xiaomin Lu; Thomas J. George
• Keywords: 0301 basic medicine; 03 medical and health sciences; 3. Good health

e15201 Background: Survival after pancreatic adenocarcinoma (PCa) resection is only 20% despite adjuvant therapy. Neoadjuvant treatment (NAT) is cost effective, may improve R0 resection rates and m...